U.S. and European Union Osteoporosis Drugs Market Dominated by Bisphosphonates

The U.S. osteoporosis drugs market will reach USD 9,105.2 million by 2030, growing at a CAGR of 4.90%. Similarly, the EU osteoporosis drugs market revenue will be USD 4,265.4 million by the end of this decade, with a 4.65% CAGR, as stated by P&S Intelligence.

The growth is attributed to the growing incidence rate of osteoporosis, the mounting geriatric population, the surging obesity cases, the expanding occurrence of lifestyle- diseases, and the escalating healthcare expenditure in the U.S. and the EU.

Download sample pages of this report: https://www.psmarketresearch.com/market-analysis/us-eu-osteoporosis-drugs-market/report-sample

On the basis of type, the bisphosphonates category had the largest revenue share, and it will maintain its ascendency in the years to come. This is because bisphosphonates have proved efficiency to minimalize fracture risk at the spine, hip and other non-vertebral skeletal sites, surge the survival rate, and decrease the considerable risk of morbidity.

Furthermore, the increasing count of women in the post-menopausal stage and an increase in the occurrence of bone diseases will further contribute to the requirement for these kinds of drugs.

According to the WHO, healthcare spending is snowballing globally, as a result of the increasing incidence of ailments and the expanding government and non-government initiatives.

This brings about the development in healthcare infra and the increase in affordability and convenience of treatment and analysis for diverse medical conditions.

Make inquiry before purchase of this report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=us-eu-osteoporosis-drugs-market

On the basis of application, the primary osteoporosis category has a larger share of revenue and it will also record faster growth in the years to come.

This is because the cases that happened are of the main type, which affects women after menopause because of a sudden decrease in estrogen production; the loss of bone structure as a result of the lack of testosterone in men; and the increasing elderly populace in the U.S. and the EU.

On the basis of route of administration, the injectable category has a larger share of revenue, and it will maintain its position in the years to come.

This is for the reason most of the drugs for osteoporosis come in the form of injectables.

Moreover, this route of administration has numerous advantages for example injectable drugs don't cause stomach upset and it might be easier for some people to schedule a quarterly or yearly infusion than to reminisce to take a monthly or weekly pill.

Instead, the oral & spray category will grow significantly in the years to come. This is because of the increasing preference of people for oral & spray medication because of their ease of use.

The U.S. osteoporosis drugs market has a higher share of revenue and it will maintain its dominance in the future, and the EU osteoporosis drugs market will grow at a significant rate as stated by P&S Intelligence.

Browse full report at: https://www.psmarketresearch.com/market-analysis/us-eu-osteoporosis-drugs-market

This is as a result of the high incidence rate of bone-related ailments and osteoporosis-related fractures, the increasing count of clinics and hospitals, the increasing government investment for emerging cutting-edge healthcare infra, and the growing number of consciousness programs.

It is because of the increasing prevalence of osteoporosis, the demand for osteoporosis drugs will continue to increase in the U.S. and EU.

Contact:
Chandra Mohan
AVP - Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Blog: https://psintelligence.blogspot.com

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

This release was published on openPR.